| Popis: |
According to the forecasts of the World Health Organization, non-alcoholic fatty liver disease (NAFLD) will rank first in the structure of liver diseases by 2020. The article presents the current provisions on the pathogenesis of NAFLD, as well as existing and promising directions in the treatment of non-alcoholic fatty liver disease. A review of the recommendations of the leading hepatological associations for the treatment of non-alcoholic fatty liver disease is carried out. The main directions in the pharmacological treatment of NAFLD are the prescription of drugs that reduce body weight, increase the sensitivity of tissues to insulin, affect oxidative stress, normalize the levels of lipids and blood transaminases, and correct intestinal microflora. |
